Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Autor: Kolev VN; Verastem, Inc., Needham, MA, USA., Tam WF; Verastem, Inc., Needham, MA, USA., Wright QG; Verastem, Inc., Needham, MA, USA., McDermott SP; Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Vidal CM; Verastem, Inc., Needham, MA, USA., Shapiro IM; Verastem, Inc., Needham, MA, USA., Xu Q; Verastem, Inc., Needham, MA, USA., Wicha MS; Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA., Pachter JA; Verastem, Inc., Needham, MA, USA., Weaver DT; Verastem, Inc., Needham, MA, USA.

Publikováno v: Oncotarget [Oncotarget] 2017 Jun 16; Vol. 8 (31), pp. 51733-51747. Date of Electronic Publication: 2017 Jun 16 (Print Publication: 2017).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pyk2 promotes tumor progression in multiple myeloma.

Autor: Zhang Y; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; The First People's Hospital of Yunnan Province, Department of Gastroenterology, Kunming, China;, Moschetta M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Huynh D; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Tai YT; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Zhang Y; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Zhang W; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Nanfang Hospital, Southern Medical University, Guangzhou, China; and., Mishima Y; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Ring JE; Verastem Inc., Cambridge, MA., Tam WF; Verastem Inc., Cambridge, MA., Xu Q; Verastem Inc., Cambridge, MA., Maiso P; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Reagan M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Sahin I; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Sacco A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Manier S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Aljawai Y; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Glavey S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Munshi NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Pachter J; Verastem Inc., Cambridge, MA., Roccaro AM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;, Ghobrial IM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

Publikováno v: Blood [Blood] 2014 Oct 23; Vol. 124 (17), pp. 2675-86. Date of Electronic Publication: 2014 Sep 12.

Focal adhesion kinase: from biological functions to therapeutic strategies.

Autor: Tan, Ximin¹ (AUTHOR), Yan, Yuheng¹ (AUTHOR), Song, Bin² (AUTHOR), Zhu, Shuangli¹ (AUTHOR), Mei, Qi² (AUTHOR) borismq@163.com, Wu, Kongming^2,3 (AUTHOR) wukm_lab@163.com

Publikováno v: Experimental Hematology & Oncology. 9/25/2023, Vol. 12 Issue 1, p1-19. 19p.